Immix Biopharma (IMMX) Competitors $2.27 +0.08 (+3.65%) Closing price 08/15/2025 04:00 PM EasternExtended Trading$2.27 0.00 (0.00%) As of 08/15/2025 04:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMMX vs. RNAC, ALT, LFCR, CRVS, SGMT, TLSA, HRTX, OCGN, SCPH, and GLUEShould you be buying Immix Biopharma stock or one of its competitors? The main competitors of Immix Biopharma include Cartesian Therapeutics (RNAC), Altimmune (ALT), Lifecore Biomedical (LFCR), Corvus Pharmaceuticals (CRVS), Sagimet Biosciences (SGMT), Tiziana Life Sciences (TLSA), Heron Therapeutics (HRTX), Ocugen (OCGN), scPharmaceuticals (SCPH), and Monte Rosa Therapeutics (GLUE). These companies are all part of the "pharmaceutical products" industry. Immix Biopharma vs. Its Competitors Cartesian Therapeutics Altimmune Lifecore Biomedical Corvus Pharmaceuticals Sagimet Biosciences Tiziana Life Sciences Heron Therapeutics Ocugen scPharmaceuticals Monte Rosa Therapeutics Cartesian Therapeutics (NASDAQ:RNAC) and Immix Biopharma (NASDAQ:IMMX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, media sentiment, dividends, institutional ownership, earnings, analyst recommendations, profitability and valuation. Which has better valuation and earnings, RNAC or IMMX? Immix Biopharma has lower revenue, but higher earnings than Cartesian Therapeutics. Immix Biopharma is trading at a lower price-to-earnings ratio than Cartesian Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCartesian Therapeutics$38.91M7.57-$77.42M-$52.83-0.21Immix BiopharmaN/AN/A-$21.61M-$0.77-2.95 Is RNAC or IMMX more profitable? Cartesian Therapeutics' return on equity of 0.00% beat Immix Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Cartesian TherapeuticsN/A N/A -6.36% Immix Biopharma N/A -205.35%-110.63% Does the media favor RNAC or IMMX? In the previous week, Cartesian Therapeutics had 2 more articles in the media than Immix Biopharma. MarketBeat recorded 4 mentions for Cartesian Therapeutics and 2 mentions for Immix Biopharma. Immix Biopharma's average media sentiment score of 1.44 beat Cartesian Therapeutics' score of 0.62 indicating that Immix Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cartesian Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immix Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, RNAC or IMMX? Cartesian Therapeutics has a beta of 0.44, meaning that its share price is 56% less volatile than the S&P 500. Comparatively, Immix Biopharma has a beta of 0.28, meaning that its share price is 72% less volatile than the S&P 500. Do insiders & institutionals hold more shares of RNAC or IMMX? 87.0% of Cartesian Therapeutics shares are held by institutional investors. Comparatively, 11.3% of Immix Biopharma shares are held by institutional investors. 60.3% of Cartesian Therapeutics shares are held by company insiders. Comparatively, 55.4% of Immix Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Do analysts rate RNAC or IMMX? Cartesian Therapeutics currently has a consensus price target of $40.00, suggesting a potential upside of 253.05%. Immix Biopharma has a consensus price target of $7.00, suggesting a potential upside of 208.37%. Given Cartesian Therapeutics' higher probable upside, analysts clearly believe Cartesian Therapeutics is more favorable than Immix Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cartesian Therapeutics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80Immix Biopharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryCartesian Therapeutics beats Immix Biopharma on 10 of the 14 factors compared between the two stocks. Get Immix Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for IMMX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IMMX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMMX vs. The Competition Export to ExcelMetricImmix BiopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$65.44M$3.14B$5.71B$9.78BDividend YieldN/A2.21%3.90%4.10%P/E Ratio-2.9521.0331.1325.06Price / SalesN/A233.41402.9788.21Price / CashN/A41.5625.2228.44Price / Book4.739.649.255.96Net Income-$21.61M-$54.74M$3.26B$265.21M7 Day Performance-2.16%6.65%4.43%2.71%1 Month Performance-23.57%5.81%4.80%1.01%1 Year Performance19.47%15.86%30.34%24.69% Immix Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMMXImmix Biopharma3.874 of 5 stars$2.27+3.7%$7.00+208.4%+19.5%$65.44MN/A-2.959Positive NewsRNACCartesian Therapeutics2.3697 of 5 stars$11.31-4.4%$40.00+253.8%-20.3%$290.38M$38.91M-0.2164ALTAltimmune3.1967 of 5 stars$3.57-2.9%$18.20+410.5%-44.1%$289.16M$20K-2.8350Trending NewsEarnings ReportAnalyst RevisionLFCRLifecore Biomedical0.7632 of 5 stars$7.67+5.8%$8.00+4.3%+28.2%$283.84M$128.26M-5.29690News CoverageAnalyst UpgradeCRVSCorvus Pharmaceuticals2.8966 of 5 stars$4.14-3.6%$15.00+262.8%+32.4%$281.88MN/A-4.2230SGMTSagimet Biosciences3.1923 of 5 stars$9.13+1.8%$26.83+194.1%+178.9%$279.86M$2M-5.188Earnings ReportTLSATiziana Life Sciences0.7786 of 5 stars$2.38+3.9%N/A+62.8%$278.69MN/A0.008HRTXHeron Therapeutics4.1437 of 5 stars$1.83+0.8%$5.00+174.0%-31.1%$278.42M$144.29M-30.42300Positive NewsOCGNOcugen1.5368 of 5 stars$0.95-0.3%$6.00+530.3%-15.3%$278.31M$4.05M-4.7680SCPHscPharmaceuticals4.5025 of 5 stars$5.11-5.6%$14.00+174.2%-11.4%$270.39M$36.33M-2.6830Short Interest ↓GLUEMonte Rosa Therapeutics2.8221 of 5 stars$4.37-9.6%$15.33+251.3%-2.1%$269.11M$75.62M54.6990Positive News Related Companies and Tools Related Companies Cartesian Therapeutics Competitors Altimmune Competitors Lifecore Biomedical Competitors Corvus Pharmaceuticals Competitors Sagimet Biosciences Competitors Tiziana Life Sciences Competitors Heron Therapeutics Competitors Ocugen Competitors scPharmaceuticals Competitors Monte Rosa Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMMX) was last updated on 8/18/2025 by MarketBeat.com Staff From Our PartnersWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThe Coin That Could Define Trump’s Crypto PresidencyWhen Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top ad...Weiss Ratings | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | SponsoredGENIUS Act: Cancel Your Money?They said digital dollars were off the table. But with the GENIUS Act now federal law, private corporations—no...Priority Gold | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immix Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immix Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access